According to a recent LinkedIn post from C Ray Therapeutics, the company is highlighting a partnership with TRUKING TECHNOLOGY LIMITED and the use of STÄUBLI Stericlean robots in its radiopharmaceutical automation efforts. The post emphasizes attributes such as precision, reliability, and adherence to global GMP standards in aseptic production, positioning these capabilities as important for targeted cancer therapy development.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
For investors, the collaboration suggests C Ray Therapeutics is investing in advanced manufacturing automation, which could support scalable and compliant production of radioligand therapies. This focus on GMP-compliant, automated aseptic processing may enhance the company’s ability to move from development to commercial-scale supply in isotopes such as Ac225 and Lu177, potentially strengthening its competitive position in the radiopharmaceutical and targeted oncology markets.